Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Capital Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Leases fell 34.32% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 34.32% decrease, with the full-year FY2025 number at $1.5 million, down 34.32% from a year prior.
  • Capital Leases was $1.5 million for Q4 2025 at Kymera Therapeutics, down from $1.8 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $2.2 million in Q4 2024 to a low of $498000.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $1.2 million in 2021 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: crashed 48.78% in 2022, then soared 171.23% in 2024.
  • Kymera Therapeutics' Capital Leases stood at $1.1 million in 2021, then grew by 9.3% to $1.2 million in 2022, then rose by 4.41% to $1.3 million in 2023, then surged by 71.1% to $2.2 million in 2024, then plummeted by 34.32% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Capital Leases are $1.5 million (Q4 2025), $1.8 million (Q3 2025), and $2.2 million (Q2 2025).